Early daratumumab or immunomodulatory agents in high-risk smoldering multiple myeloma show uncertain benefits versus observation.
Early Drug May Delay Multiple Myeloma
This systematic review evaluated early intervention with monoclonal antibodies, immunomodulatory agents, or alkylating agents versus observa…
Imagine waking up with a headache. You take a pill, and the pain goes away.
Siltuximab shows partial response in two iMCD-IPL cases with xanthelasma; skin lesions unchanged
Two patients with rare Castleman disease had xanthelasma that did not improve with treatment.
A case report describes two Asian women in their 5th decade with idiopathic plasmacytic lymphadenopathy subtype of idiopathic multicentric C…
Two women with rare Castleman disease saw their skin inflammation improve but stubborn yellow eyelid patches stayed despite treatment.